GlaxoSmithKline Pharmaceuticals Ltd

Profit before tax was at Rs 369.12 crore in the March 2026 quarter, up 4% from Rs 354.9 crore recorded in corresponding quarter last year. Total expenses marginally rose 0.78% to Rs 655.75 crore in Q4 FY26 over Q4 FY25. Cost of materials consumed was at Rs 101.47 crore (down 6.34% YoY) while employee benefits expense stood at Rs 164.75 crore (up 7.70% YoY) during the period under review. EBITDA stood at Rs 347 crore in the quarter, up 5% year-on-year. EBITDA margin improved by 90 basis points to 35.1%. The General Medicines portfolio delivered a competitive performance during the quarter, with the top four promoted brands outperforming the market, according to IQVIA data. Key brands including Augmentin, Calpol and T-Bact continued to maintain leadership positions in their respective categories, although the tail-end distributed portfolio faced significant headwinds. The Vaccines business registered growth driven by strong demand and sustained leadership in the self-pay private paediatric vaccines segment. Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted) achieved critical scale during the year amid rising awareness around preventive healthcare and adult immunisation. The Oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), continued to witness strong traction. During the year, Jemperli received first-line approval from Indian regulators for primary advanced and recurrent endometrial cancer, significantly expanding the eligible patient pool and supporting long-term growth prospects in the oncology segment. The company has received market authorisation in India for Blenrep (belantamab mafodotin), an anti-BCMA antibody-drug conjugate (ADC) therapy indicated for the treatment of relapsed or refractory multiple myeloma in adults. Multiple myeloma is the third most common blood cancer globally, with around 180,000 new cases diagnosed annually. The company said launch plans for the therapy will be announced at an appropriate time. Bhushan Akshikar, Managing Director, GSK India, said: 'The strong delivery of our Oncology portfolio signals a key inflection point in GSK India's journey to evolve into an innovation-led company, focused on areas of high unmet medical need. Our progress is underpinned by scientific rigour, disciplined execution and an unwavering commitment to our patients in India. Building on this momentum, we will continue to invest in innovative, high-growth therapy areas to make a positive impact at scale. Our ambition is driven by a sharp focus on topline growth and sustainable profitability.' The board has recommended a final dividend of Rs 57 per equity share of face value Rs 10 each for the financial year ended March 31, 2026. The company has fixed May 29, 2026, as the record date for determining eligible shareholders for the final dividend. If approved at the AGM, the dividend will be paid on or after July 1, 2026, subject to deduction of tax at source. GlaxoSmithKline Pharmaceuticals is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together.Powered by Capital Market - Live

Net profit of Glaxosmithkline Pharmaceuticals rose 5.70% to Rs 277.86 crore in the quarter ended March 2026 as against Rs 262.87 crore during the previous quarter ended March 2025. Sales rose 2.15% to Rs 995.30 crore in the quarter ended March 2026 as against Rs 974.37 crore during the previous quarter ended March 2025. For the full year,net profit rose 11.69% to Rs 1035.98 crore in the year ended March 2026 as against Rs 927.58 crore during the previous year ended March 2025. Sales rose 1.93% to Rs 3821.67 crore in the year ended March 2026 as against Rs 3749.21 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales995.30974.37 2 3821.673749.21 2 OPM %35.2634.20 -34.2631.40 - PBDT386.27373.29 3 1451.831321.98 10 PBT373.10358.57 4 1385.391255.19 10 NP277.86262.87 6 1035.98927.58 12 Powered by Capital Market - Live

Profit before tax was at Rs 369.12 crore in the March 2026 quarter, up 4% from Rs 354.9 crore recorded in corresponding quarter last year. Total expenses marginally rose 0.78% to Rs 655.75 crore in Q4 FY26 over Q4 FY25. Cost of materials consumed was at Rs 101.47 crore (down 6.34% YoY) while employee benefits expense stood at Rs 164.75 crore (up 7.70% YoY) during the period under review. EBITDA stood at Rs 347 crore in the quarter, up 5% year-on-year. EBITDA margin improved by 90 basis points to 35.1%. The General Medicines portfolio delivered a competitive performance during the quarter, with the top four promoted brands outperforming the market, according to IQVIA data. Key brands including Augmentin, Calpol and T-Bact continued to maintain leadership positions in their respective categories, although the tail-end distributed portfolio faced significant headwinds. The Vaccines business registered growth driven by strong demand and sustained leadership in the self-pay private paediatric vaccines segment. Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted) achieved critical scale during the year amid rising awareness around preventive healthcare and adult immunisation. The Oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), continued to witness strong traction. During the year, Jemperli received first-line approval from Indian regulators for primary advanced and recurrent endometrial cancer, significantly expanding the eligible patient pool and supporting long-term growth prospects in the oncology segment. The company has received market authorisation in India for Blenrep (belantamab mafodotin), an anti-BCMA antibody-drug conjugate (ADC) therapy indicated for the treatment of relapsed or refractory multiple myeloma in adults. Multiple myeloma is the third most common blood cancer globally, with around 180,000 new cases diagnosed annually. The company said launch plans for the therapy will be announced at an appropriate time. Bhushan Akshikar, Managing Director, GSK India, said: 'The strong delivery of our Oncology portfolio signals a key inflection point in GSK India's journey to evolve into an innovation-led company, focused on areas of high unmet medical need. Our progress is underpinned by scientific rigour, disciplined execution and an unwavering commitment to our patients in India. Building on this momentum, we will continue to invest in innovative, high-growth therapy areas to make a positive impact at scale. Our ambition is driven by a sharp focus on topline growth and sustainable profitability.' The board has recommended a final dividend of Rs 57 per equity share of face value Rs 10 each for the financial year ended March 31, 2026. The company has fixed May 29, 2026, as the record date for determining eligible shareholders for the final dividend. If approved at the AGM, the dividend will be paid on or after July 1, 2026, subject to deduction of tax at source. GlaxoSmithKline Pharmaceuticals is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together. Shares of GlaxoSmithKline Pharmaceuticals declined 1.68% to end at Rs 2,406.85 on the BSE. Powered by Capital Market - Live

GlaxoSmithKline Pharmaceuticals announced that the 101th Annual General Meeting(AGM) of the company will be held on 30 June 2026.

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 13 May 2026, has recommended a Final Dividend of Rs.57 per share (i.e.570%), subject to the approval of the shareholders.

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 May 2026.

Glaxosmithkline Pharmaceuticals announced that Vinay Subramanian, Commercial Head - Oncology would be part of leadership team effective 20 April 2026 based out of Mumbai, and he would be part of senior Management Personnel of the Company effective the said date. Vinay brings with him over 24 years of experience in the Pharmaceuticals, Life Science. Healthcare Devices, and Medical Technology sectors. Prior to joining GSK. he served as the India Enabling leader - Enterprise & Neighboring Countries at Roche Products India Pvt ltd. where he was responsible for the immunotherapy portfolio and was part of their leadership team.

Net profit of Glaxosmithkline Pharmaceuticals rose 28.60% to Rs 295.62 crore in the quarter ended December 2025 as against Rs 229.88 crore during the previous quarter ended December 2024. Sales rose 9.67% to Rs 1041.26 crore in the quarter ended December 2025 as against Rs 949.42 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1041.26949.42 10 OPM %35.6630.75 - PBDT402.27326.90 23 PBT381.95308.10 24 NP295.62229.88 29 Powered by Capital Market - Live

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

The key equity benchmarks traded with substantial losses in early trade, supported by weak global cues. Investors will keep a close watch on the ongoing Q2 earnings season, crude oil prices and other global developments. The Nifty slipped above the 25,350 mark. All the sectoral indices on the NSE were traded in red with IT, consumer durables and PSU Bank shares declining the most. At 09:25 IST, the barometer index, the S&P BSE Sensex, declined 448.20 points or 0.54% to 82,862.81. The Nifty 50 index fell 173.75 points or 0.68% to 25,335.85. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index fell 0.96% and the S&P BSE Small-Cap index tumbled 1.18%. The market breadth was weak. On the BSE, 869 shares rose and 2,141 shares fell. A total of 147 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth Rs 3,263.21 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 5,283.91 crore in the Indian equity market on 06 November 2025, provisional data showed. Numbers to Track: The yield on India's 10-year benchmark federal paper rose 0.14% to 6,523 from the previous close of 6.514. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 88.6550 compared with its close of 88.6300 during the previous trading session. MCX Gold futures for 5 December 2025 settlement rose 0.25% to Rs 120,911. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.08% to 99.79. The United States 10-year bond yield fell 0.07% to 4.090. In the commodities market, Brent crude for December 2025 settlement advanced 19 cents or 0.30% to $63.57 a barrel. Stocks in Spotlight: GlaxoSmithKline Pharmaceuticals fell 1.45%. The company reported a 2% year-on-year increase in consolidated net profit to Rs 257 crore for the quarter, compared with Rs 253 crore in the same period last year. Revenue from operations declined 3.1% to Rs 980 crore from Rs 1,011 crore a year ago. Crompton Greaves Consumer Electricals declined 1.53% after the company reported a 43% year-on-year decline in consolidated net profit to Rs 71.2 crore for the quarter, compared with Rs 125 crore in the same period last year. Revenue rose 1% to Rs 1,916 crore from Rs 1,896 crore a year ago. GMM Pfaudler fell 2.81%. The company reported a sharp rise in consolidated net profit to Rs 41.4 crore for the quarter, compared with Rs 15.2 crore in the corresponding period last year. Revenue grew 12% year-on-year to Rs 902 crore from Rs 805 crore. Global Markets: Asia market declined on Friday, mirroring Wall Street's losses as renewed concerns over stretched valuations in artificial intelligence (AI) stocks weighed on sentiment. Investors across the region are now awaiting China's October trade data, expected later in the day. Media reports indicate that exports may have grown just 3% year-on-year, slowing sharply from 8.3% in September, while imports are forecast to fall 3.2% after rising 7.4% previously. The slowdown reflects weak domestic demand, prolonged pressure from the property downturn, rising job insecurity, and the fading impact of earlier consumption stimulus. On Wall Street, AI-linked stocks extended their recent declines, dragging major indices lower. The Dow Jones Industrial Average fell 398.70 points (0.84%) to 46,912.30, while the S&P 500 dropped 1.12% to 6,720.32. The Nasdaq Composite tumbled 1.9% to 23,053.99, with the Nasdaq 100 down more than 2% for the week ' its steepest decline since early April. Adding to investor unease, October layoffs surged to 153,000, nearly triple September's figure and 175% higher year-on-year, according to Challenger, Gray & Christmas. The spike in job cuts, combined with the ongoing U.S. government shutdown, now over a month old, has further clouded the outlook for the U.S. economy.Powered by Capital Market - Live